This 2022 recommendation from the US Preventive Services Task Force (USPSTF) advises against the use of hormone therapy—either combined estrogen and progestin or estrogen alone—for the primary prevention of chronic conditions such as cardiovascular disease, osteoporosis, and cancer in asymptomatic postmenopausal individuals. The USPSTF assigns a Grade D recommendation, indicating
